Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis-Reference-Cited by-同舟云学术

Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

Published:2016-07-22 Issue:9 Volume:65 Page:1099-1111
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Takahashi Hidenori, ,Shimodaira Shigetaka,Ogasawara Masahiro,Ota Shuichi,Kobayashi Masanori,Abe Hirofumi,Morita Yuji,Nagai Kazuhiro,Tsujitani Shunichi,Okamoto Masato,Suzuki Yukio,Nakanishi Yoichi,Yonemitsu Yoshikazu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1872-z.pdf

Reference38 articles.

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

2. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173–181

3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 346:92–98

4. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323

5. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J et al (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084–3092

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review;Frontiers in Immunology;2024-09-06

2. The current therapeutic cancer vaccines landscape in non‐small cell lung cancer;International Journal of Cancer;2024-08-07

3. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy;Biomedicine & Pharmacotherapy;2023-10

4. Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer;Journal of the National Cancer Center;2022-12

5. Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer;Journal of the National Cancer Center;2022-12